XDH and metabolic dysfunction-associated steatotic liver disease: In contrast to allopurinol, in the NAFLD mouse model, febuxostat reduced UA levels and xanthine oxidase activity and more effectively reduced insulin resistance, lipid peroxidation, and liver inflammation, suggesting that febuxostat plays a more efficient role in preventing liver metastasis [45].